Effects of Z-100, a Mycobacterium-tuberculosis-derived arabinomannan, on the LP-BM5 murine leukemia virus infection in mice.

Abstract

OBJECTIVE:

To investigate the effects of Z-100, an arabinomannan extracted from Mycobacterium tuberculosis, on the LP-BM5 murine leukemia virus (LP-BM5 MuLV) infection in mice.

METHODS:

C57BL/6 mice infected intraperitoneally with 4.5 x 10(2) PFU/mouse of LP-BM5 MuLV (MAIDS mice) were treated intraperitoneally with a 10-mg/kg dose of Z-100 every other day beginning 1 day after the viral infection. MAIDS mice treated with Z-100 were compared with control mice (MAIDS mice treated with saline) for their survival and splenomegaly after LP-BM5 infection. Cytokine-producing profiles of splenic T cells from these two groups of mice were also compared.

RESULTS:

When MAIDS mice treated with Z-100 were compared with those of control mice, a decrease in splenomegaly and lymphadenopathy was observed. Splenomegaly was markedly enhanced in MAIDS mice treated intraperitoneally with IL-4 or IL-10. When MAIDS mice were treated with Z-100, their survival rates were significantly increased compared to those of controls. Splenic T cells from control mice produced type-2 cytokines (IL-4 and IL-10). However, a decreased production of type-2 cytokines by splenic T cells from MAIDS mice treated with Z-100 was demonstrated.

CONCLUSION:

Z-100 could decrease the severity of the LP-BM5 MuLV infection through the regulation of MAIDS-associated type-2 T-cell responses.

• Authors: H Sasaki, M Kobayashi, R B Pollard, F Suzuki
• Journal: Pathobiology : journal of immunopathology, molecular and cellular biology (Pathobiology) Vol. 69 Issue 2 Pg. 96-103 ( 2001) ISSN: 1015-2008 [Print] Switzerland
• PMID: 11752903 (Publication Type: Journal Article)
• Copyright: Copyright 2001 S. Karger AG, Basel

Chemical References

• Anti-HIV Agents
• Lipids
• Mannans
• specific substance maruyama
• Interleukin-10
• Interleukin-4

Topics

• Animals
• Anti-HIV Agents (therapeutic use)
• Drug Antagonism
• Interleukin-10 (biosynthesis, pharmacology)
• Interleukin-4 (biosynthesis, pharmacology)
• Leukemia Virus, Murine (pathogenicity, physiology)
• Lipids (therapeutic use)
• Lymphatic Diseases (drug therapy, pathology)
• Male
• Mannans (therapeutic use)
• Mice
• Mice, Inbred C57BL
• Murine Acquired Immunodeficiency Syndrome (drug therapy, mortality)
• Organ Size (drug effects)
• Specific Pathogen-Free Organisms
• Spleen (drug effects, metabolism, pathology)
• Splenomegaly (drug therapy, pathology)
• Survival Rate
• T-Lymphocytes (drug effects, metabolism, pathology)